Laura is a science news writer, covering a wide variety of subjects, but she is particularly fascinated by all things aquatic, paleontology, nanotechnology, and exploring how science influences daily life. Laura is a proud former resident of the New Jersey shore, a competitive swimmer, and a fierce defender of the Oxford comma.
On November 8, the United States Food and Drug Administration approved a Type 2 diabetes drug called tirzepatide for use in chronic weight management. It has been sold under the brand name Mounjaro for treating diabetes, but it will be called Zepbound when prescribed for weight loss. The drug is made by pharmaceutical company Eli Lilly and doses should be available after Thanksgiving. How Zepbound works The medicine is a weekly injectable medication and the main ingredient is called tirzepatide.
“In light of increasing rates of both obesity and overweight in the United States, today’s approval addresses an unmet medical need.” How effective is Zepbound? The FDA’s approval comes on the heels of a phase 3 clinical trial. All of the participants in the study had obesity or were overweight and had at least one weight-related condition. At the highest dosage of tirzepatide participants saw an average weight loss 22.5 percent body weight, or about 52 pounds, over a period of 72 weeks.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Eli Lilly's Obesity Drug Gets FDA ApprovalThe drug will be marketed as an obesity treatment under the name Zepbound.
Read more »
FDA approves new obesity drug from Eli Lilly named ZepboundThe decision by the Food and Drug Administration is expected to add to the demand for a new class of drugs transforming how patients battle obesity.
Read more »
Zepbound: FDA approves new version of diabetes drug Mounjaro for weight lossThe U.S. Food and Drug Administration on Wednesday approved a new version of the type 2 diabetes drug tirzepatide for use in chronic weight management, officials said.
Read more »
FDA approves diabetes drug Zepbound to help obese patients lose weightStudies suggest Zepbound can help people lose weight with diet and exercise.
Read more »